Resolution of cardiac surgical bleeding with the combination of 4-factor prothrombin complex concentrate and fresh frozen plasma following lack of response to fresh frozen plasma alone in a patient with severe factor XI deficiency.


Journal

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
ISSN: 1473-5733
Titre abrégé: Blood Coagul Fibrinolysis
Pays: England
ID NLM: 9102551

Informations de publication

Date de publication:
01 Jul 2023
Historique:
medline: 12 7 2023
pubmed: 3 7 2023
entrez: 3 7 2023
Statut: ppublish

Résumé

Factor XI deficiency is associated with a bleeding tendency in some patients. Factor XI helps to reduce fibrinolysis. Bleeding risk is increased in factor XI-deficient patients during surgeries with high fibrinolytic activity, including nasopharyngeal/oropharyngeal and genitourinary surgeries. Treatment options for factor XI-deficient patients include fresh frozen plasma (FFP), antifibrinolytics, recombinant factor VIIa, and factor XI concentrates (available in Australia, Canada, and some European countries). 4-factor prothrombin complex concentrate (4-factor PCC) is an extract of FFP comprised of unactivated factors II, VII, IX, and X, proteins C and S, and heparin. It has been used for cardiac surgical bleeding. We report the first case of a patient with severe factor XI deficiency and cardiac surgical bleeding, which resolved with the combination of 4-factor PCC and FFP after lack of response to FFP alone.

Identifiants

pubmed: 37395189
doi: 10.1097/MBC.0000000000001236
pii: 00001721-990000000-00087
doi:

Substances chimiques

prothrombin complex concentrates 37224-63-8
Factor XI 9013-55-2
Blood Coagulation Factors 0
Factor IX 9001-28-9

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

333-336

Informations de copyright

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

Références

Duga S, Salomon O. Congenital factor XI deficiency: an update. Semin Thromb Haemost 2013; 39:621–631.
Bolton-Maggs PHB. Factor XI deficiency -- resolving the enigma? Hematology Am Soc Hematol Educ Program 2009. 97–105.
Downes Katharine A, Sacher Ronald A. Joseph L, Andrew LS. Plasma and component therapy. Thrombosis and hemorrhage 3rd ed.New York: Lippincott Williams and Wilkins; 2003. 897–914.
Ghadimi K, Levy JH, Welsby IJ. Prothrombin complex concentrates for bleeding in the perioperative setting. Anesth Analg 2016; 122:1287–1300.
ACC News Story. 01 May 2013. FDA approves first-in-class therapy for urgent warfarin reversal in patients with acute major bleeding. Available at: https://www.acc.org/latest-in-cardiology/articles/2013/05/01/16/45/fda-approves-therapy-for-urgent-warfarin-reversal-in-patients-with-acute-major-bleeding . [Accessed 5 December 2022]
Prothrombin Complex Concentrate (Human), Kcentra Product Labeling. fda.gov/media/85512. [Accessed 05 December 2022]
Karkouti K, Bartoszko J, Grewal D, Bingley C, Armali C, Carroll J, et al. Comparison of 4-Factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA Netw Open 2021; 4:e213936.
US FDA. 21 February 2018. NovosevenRT. Available at: https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/novosevenrt . [Accessed 13 December 2022]
NovoSeven® RT, Coagulation factor VIIa (recombinant). Available at: https://www.fda.gov/media/70442/ . [Accessed 12 December 2022]
O’Connell NM. Factor XI deficiency. Semin hematol 2004; 41: (1 Suppl 1): 76–81.
Brown SA. What dose of recombinant activated factor VII should be used in patients with factor XI deficiency? Haemophilia 2005; 11:430–431.
Zangrillo A, Mizzi A, Biondi-Zoccai G. Recombinant activated factor VII in cardiac surgery: a meta-analysis. J Cardiothoracic Vasc Anesth 2009; 23:34–40.
Brase J, Finger B, He J, Wirtz K, Stun L, McMillen R, Flynn B. Analysis of outcomes using low-dose and early administration of recombinant activated factor VII in cardiac surgery. Ann Thorac Surg 2016; 102:35–40.
Mehringer SL, Klick Z, Bain J, McNeely EB, Subramanian S, Pass LJ, et al. Activated factor 7 versus 4-factor prothrombin complex concentrate for critical bleeding postcardiac surgery. Ann Pharmacother 2018; 52:533–537.
Katz A, Ahuja T, Arnouk S, Lewis TC, Marsh K, Papadopoulos J, Merchan C. A comparison of prothrombin complex concentrate and recombinant activated factor VII for the management of bleeding with cardiac surgery. J Intensive Care Med 2022; 37:231–239.
Prothrombin complex concentrate (human) [(factors II, VII, IX, X), protein C, and protein S]; Factor VIIa (recombinant). Available at: http://online.lexi.com/ . [Accessed 11 December 2022]
Drugs.com. Prothrombin Complex Concentrate. Available at: https://www.drugs.com/monograph/prothrombin-complex-concentrate.html/ . [Accessed 12 December 2022]

Auteurs

Percy Boateng (P)

Cardiothoracic Surgery.

Mala Varma (M)

Hematology-Oncology, Mount Sinai Health System New York, New York, USA.

Lilyanne Chen (L)

Cardiothoracic Surgery.

Hein Kyaw (H)

Hematology-Oncology, Mount Sinai Health System New York, New York, USA.

Nay Lin Kyaw (NL)

Hematology-Oncology, Mount Sinai Health System New York, New York, USA.

Joseph Yoe (J)

Hematology-Oncology, Mount Sinai Health System New York, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH